AstraZeneca Financial Results: Strong Revenue G...

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rate...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
National HealthTech Access: Transforming NHS Adoption and Equity
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Accelerating FAST-EU Clinical Trials
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen